These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20141832)

  • 21. Isolation of a new protein factor required for activation of Raf-1 by Ha-Ras: partial purification from rat brain cytosols.
    Mizutani S; Koide H; Kaziro Y
    Oncogene; 1998 May; 16(21):2781-6. PubMed ID: 9652745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway.
    Waldmann H; Karaguni IM; Carpintero M; Gourzoulidou E; Herrmann C; Brockmann C; Oschkinat H; Müller O
    Angew Chem Int Ed Engl; 2004 Jan; 43(4):454-8. PubMed ID: 14735533
    [No Abstract]   [Full Text] [Related]  

  • 23. Selective activation of Ha-ras(val12) oncogene increases susceptibilityof NIH/3T3 cells to TNF-alpha.
    Chang MY; Won SJ; Yang BC; Jan MS; Liu HS
    Exp Cell Res; 1999 May; 248(2):589-98. PubMed ID: 10222151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel pyrazolopyrimidines as highly potent B-Raf inhibitors.
    Di Grandi MJ; Berger DM; Hopper DW; Zhang C; Dutia M; Dunnick AL; Torres N; Levin JI; Diamantidis G; Zapf CW; Bloom JD; Hu Y; Powell D; Wojciechowicz D; Collins K; Frommer E
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6957-61. PubMed ID: 19875283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin cancer. Golden age of melanoma therapy.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Jan; 12(1):1. PubMed ID: 25511188
    [No Abstract]   [Full Text] [Related]  

  • 26. BRAF inhibitor induced verrucal keratosis.
    Anforth R; Fernandez-Penas P
    Am J Dermatopathol; 2014 Feb; 36(2):192. PubMed ID: 23435364
    [No Abstract]   [Full Text] [Related]  

  • 27. The Ludwig institute for cancer research Melbourne melanoma cell line panel.
    Behren A; Anaka M; Lo PH; Vella LJ; Davis ID; Catimel J; Cardwell T; Gedye C; Hudson C; Stan R; Cebon J
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):597-600. PubMed ID: 23527996
    [No Abstract]   [Full Text] [Related]  

  • 28. At the crossroads of targeted treatment and resistance in melanoma.
    Masuda S; Izpisua Belmonte JC
    Lancet Oncol; 2013 Apr; 14(4):e136-7. PubMed ID: 23561743
    [No Abstract]   [Full Text] [Related]  

  • 29. PMCA4b as tumor suppressor: The Ca
    Parys JB
    Int J Cancer; 2017 Jun; 140(12):2632-2633. PubMed ID: 27859141
    [No Abstract]   [Full Text] [Related]  

  • 30. Comprehensive Reporting in Cost-Effectiveness Modeling.
    Benedict Á; Ambavane A; Tarhini A
    J Clin Oncol; 2017 Sep; 35(26):3085-3086. PubMed ID: 28715247
    [No Abstract]   [Full Text] [Related]  

  • 31. Reply to D.T.W. Jones et al.
    Tabori U; Bouffet E; Hawkins CE
    J Clin Oncol; 2018 Jan; 36(1):97. PubMed ID: 29140773
    [No Abstract]   [Full Text] [Related]  

  • 32. Reply to Dr Ozden et al.
    Decaussin-Petrucci M; Descotes F; Lifante JC; Borson-Chazot F; Lopez J
    Cytopathology; 2018 Dec; 29(6):599. PubMed ID: 30084521
    [No Abstract]   [Full Text] [Related]  

  • 33. Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.
    Wang P; Laster K; Jia X; Dong Z; Liu K
    Mol Cancer; 2023 Dec; 22(1):208. PubMed ID: 38111008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous blocking of the pan-RAF and S100B pathways as a synergistic therapeutic strategy against malignant melanoma.
    Wu KJ; Ho SH; Wu C; Wang HD; Ma DL; Leung CH
    J Cell Mol Med; 2021 Feb; 25(4):1972-1981. PubMed ID: 33377602
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape.
    Vanni I; Tanda ET; Spagnolo F; Andreotti V; Bruno W; Ghiorzo P
    Front Mol Biosci; 2020; 7():113. PubMed ID: 32695793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.
    Degirmenci U; Wang M; Hu J
    Cells; 2020 Jan; 9(1):. PubMed ID: 31941155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.
    Zhou AY; Johnson DB
    Am J Clin Dermatol; 2018 Apr; 19(2):181-193. PubMed ID: 28861871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.
    Peng S; Sen B; Mazumdar T; Byers LA; Diao L; Wang J; Tong P; Giri U; Heymach JV; Kadara HN; Johnson FM
    Oncotarget; 2016 Jan; 7(1):565-79. PubMed ID: 26623721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.
    Mazumdar T; Sen B; Wang Y; Peng S; Nicholas C; Glisson BS; Myers JN; Johnson FM
    Anticancer Drugs; 2015 Sep; 26(8):835-42. PubMed ID: 26053277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAF Mutation in Hairy Cell Leukemia.
    Ahmadzadeh A; Shahrabi S; Jaseb K; Norozi F; Shahjahani M; Vosoughi T; Hajizamani S; Saki N
    Oncol Rev; 2014 Sep; 8(2):253. PubMed ID: 25992240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.